Skip to main content
NASDAQ:DYAI

Dyadic International Competitors

$3.82
-0.02 (-0.52 %)
(As of 05/14/2021 01:35 PM ET)
Add
Compare
Today's Range
$3.51
$3.88
50-Day Range
$3.80
$5.67
52-Week Range
$3.64
$10.98
Volume3,500 shs
Average Volume467,884 shs
Market Capitalization$105.26 million
P/E RatioN/A
Dividend YieldN/A
Beta0.14

Competitors

Dyadic International (NASDAQ:DYAI) Vs. OYST, APTO, GRTS, JNCE, CDAK, and AVRO

Should you be buying DYAI stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Dyadic International, including Oyster Point Pharma (OYST), Aptose Biosciences (APTO), Gritstone bio (GRTS), Jounce Therapeutics (JNCE), Codiak BioSciences (CDAK), and AVROBIO (AVRO).

Oyster Point Pharma (NASDAQ:OYST) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Oyster Point Pharma and Dyadic International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oyster Point PharmaN/A-39.61%-37.68%
Dyadic International-539.34%-27.54%-26.33%

Volatility and Risk

Oyster Point Pharma has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oyster Point Pharma and Dyadic International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oyster Point Pharma00103.00
Dyadic International00103.00

Dyadic International has a consensus price target of $11.00, indicating a potential upside of 183.51%. Given Dyadic International's higher possible upside, analysts plainly believe Dyadic International is more favorable than Oyster Point Pharma.

Insider & Institutional Ownership

70.2% of Oyster Point Pharma shares are owned by institutional investors. Comparatively, 20.2% of Dyadic International shares are owned by institutional investors. 36.9% of Oyster Point Pharma shares are owned by insiders. Comparatively, 23.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Oyster Point Pharma and Dyadic International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-1.64
Dyadic International$1.68 million62.65$-8,310,000.00($0.31)-12.32

Dyadic International has higher revenue and earnings than Oyster Point Pharma. Dyadic International is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Dyadic International beats Oyster Point Pharma on 7 of the 11 factors compared between the two stocks.

Aptose Biosciences (NASDAQ:APTO) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Aptose Biosciences and Dyadic International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/A-49.53%-46.65%
Dyadic International-539.34%-27.54%-26.33%

Earnings and Valuation

This table compares Aptose Biosciences and Dyadic International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-9.35
Dyadic International$1.68 million62.65$-8,310,000.00($0.31)-12.32

Dyadic International has higher revenue and earnings than Aptose Biosciences. Dyadic International is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Aptose Biosciences and Dyadic International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00803.00
Dyadic International00103.00

Aptose Biosciences currently has a consensus price target of $11.6250, indicating a potential upside of 139.69%. Dyadic International has a consensus price target of $11.00, indicating a potential upside of 183.51%. Given Dyadic International's higher possible upside, analysts plainly believe Dyadic International is more favorable than Aptose Biosciences.

Volatility and Risk

Aptose Biosciences has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

Insider & Institutional Ownership

52.2% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 20.2% of Dyadic International shares are owned by institutional investors. 6.3% of Aptose Biosciences shares are owned by insiders. Comparatively, 23.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Dyadic International beats Aptose Biosciences on 7 of the 12 factors compared between the two stocks.

Dyadic International (NASDAQ:DYAI) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Dyadic International and Gritstone bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dyadic International-539.34%-27.54%-26.33%
Gritstone bio-2,962.52%-101.31%-68.78%

Valuation & Earnings

This table compares Dyadic International and Gritstone bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyadic International$1.68 million62.65$-8,310,000.00($0.31)-12.32
Gritstone bio$4.36 million97.72$-94,430,000.00($2.81)-3.08

Dyadic International has higher earnings, but lower revenue than Gritstone bio. Dyadic International is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Dyadic International and Gritstone bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dyadic International00103.00
Gritstone bio10202.33

Dyadic International presently has a consensus target price of $11.00, indicating a potential upside of 183.51%. Gritstone bio has a consensus target price of $22.3333, indicating a potential upside of 157.89%. Given Dyadic International's stronger consensus rating and higher possible upside, research analysts clearly believe Dyadic International is more favorable than Gritstone bio.

Volatility & Risk

Dyadic International has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Insider & Institutional Ownership

20.2% of Dyadic International shares are owned by institutional investors. Comparatively, 59.0% of Gritstone bio shares are owned by institutional investors. 23.9% of Dyadic International shares are owned by company insiders. Comparatively, 38.0% of Gritstone bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dyadic International (NASDAQ:DYAI) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Dyadic International and Jounce Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dyadic International-539.34%-27.54%-26.33%
Jounce TherapeuticsN/A-72.91%-59.68%

Valuation & Earnings

This table compares Dyadic International and Jounce Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyadic International$1.68 million62.65$-8,310,000.00($0.31)-12.32
Jounce Therapeutics$147.87 million2.59$56.82 million$1.664.51

Jounce Therapeutics has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Dyadic International and Jounce Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dyadic International00103.00
Jounce Therapeutics11402.50

Dyadic International presently has a consensus target price of $11.00, indicating a potential upside of 183.51%. Jounce Therapeutics has a consensus target price of $15.50, indicating a potential upside of 106.39%. Given Dyadic International's stronger consensus rating and higher possible upside, research analysts clearly believe Dyadic International is more favorable than Jounce Therapeutics.

Volatility & Risk

Dyadic International has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Jounce Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Insider & Institutional Ownership

20.2% of Dyadic International shares are owned by institutional investors. Comparatively, 60.5% of Jounce Therapeutics shares are owned by institutional investors. 23.9% of Dyadic International shares are owned by company insiders. Comparatively, 44.0% of Jounce Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Jounce Therapeutics beats Dyadic International on 9 of the 14 factors compared between the two stocks.

Dyadic International (NASDAQ:DYAI) and Codiak BioSciences (NASDAQ:CDAK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Dyadic International and Codiak BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dyadic International-539.34%-27.54%-26.33%
Codiak BioSciencesN/AN/AN/A

Valuation & Earnings

This table compares Dyadic International and Codiak BioSciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyadic International$1.68 million62.65$-8,310,000.00($0.31)-12.32
Codiak BioSciencesN/AN/AN/AN/AN/A

Codiak BioSciences has lower revenue, but higher earnings than Dyadic International.

Analyst Recommendations

This is a summary of recent ratings and price targets for Dyadic International and Codiak BioSciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dyadic International00103.00
Codiak BioSciences00303.00

Dyadic International presently has a consensus target price of $11.00, indicating a potential upside of 183.51%. Codiak BioSciences has a consensus target price of $30.00, indicating a potential upside of 67.97%. Given Dyadic International's higher possible upside, research analysts clearly believe Dyadic International is more favorable than Codiak BioSciences.

Insider & Institutional Ownership

20.2% of Dyadic International shares are owned by institutional investors. 23.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dyadic International (NASDAQ:DYAI) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Dyadic International and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dyadic International-539.34%-27.54%-26.33%
AVROBION/A-51.33%-47.65%

Valuation & Earnings

This table compares Dyadic International and AVROBIO's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyadic International$1.68 million62.65$-8,310,000.00($0.31)-12.32
AVROBION/AN/A$-72,960,000.00($2.66)-3.65

Dyadic International has higher revenue and earnings than AVROBIO. Dyadic International is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Dyadic International and AVROBIO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dyadic International00103.00
AVROBIO03602.67

Dyadic International presently has a consensus target price of $11.00, indicating a potential upside of 183.51%. AVROBIO has a consensus target price of $24.2222, indicating a potential upside of 152.58%. Given Dyadic International's stronger consensus rating and higher possible upside, research analysts clearly believe Dyadic International is more favorable than AVROBIO.

Volatility & Risk

Dyadic International has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Insider & Institutional Ownership

20.2% of Dyadic International shares are owned by institutional investors. Comparatively, 86.7% of AVROBIO shares are owned by institutional investors. 23.9% of Dyadic International shares are owned by company insiders. Comparatively, 4.8% of AVROBIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Dyadic International beats AVROBIO on 8 of the 13 factors compared between the two stocks.


Dyadic International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Oyster Point Pharma logo
OYST
Oyster Point Pharma
0.9$16.31-0.4%$422.14 millionN/A-4.70
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.86-4.9%$410.81 millionN/A-7.59
Gritstone bio logo
GRTS
Gritstone bio
1.6$8.66-5.9%$400.96 million$4.36 million-3.03Analyst Downgrade
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$7.48-3.3%$370.23 million$147.87 million-2.49
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$17.86-6.7%$367.25 millionN/A0.00Gap Up
AVROBIO logo
AVRO
AVROBIO
1.9$9.72-9.6%$367.12 millionN/A-2.95Earnings Announcement
Analyst Report
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.4$8.27-1.8%$357.39 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.8$3.67-1.4%$354.53 million$250,000.00-2.89Analyst Downgrade
Opthea logo
OPT
Opthea
1.5$8.03-3.5%$348.96 millionN/A0.00Gap Up
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.3$2.06-5.8%$336.80 million$8.15 million-1.65Upcoming Earnings
Gap Up
Surface Oncology logo
SURF
Surface Oncology
1.4$7.87-6.5%$319.64 million$15.36 million-11.92
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.57-0.9%$318.82 million$250,000.00-3.06Earnings Announcement
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.21-2.6%$316.69 million$2.91 million-2.16Analyst Report
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$11.83-4.3%$315.62 millionN/A0.00Earnings Announcement
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.7$9.44-7.3%$313.73 millionN/A0.00Analyst Report
News Coverage
Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$3.95-3.0%$312.01 million$96.12 million-11.62Gap Down
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.13-1.2%$272.63 millionN/A-3.35Analyst Report
Analyst Revision
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$9.47-7.3%$218.87 millionN/A-6.91
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.48-4.1%$198.51 million$4.13 million-3.29Earnings Announcement
Analyst Report
News Coverage
Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.78-9.0%$196.47 million$29.35 million-2.07Earnings Announcement
Genfit logo
GNFT
Genfit
1.3$4.11-1.5%$188.14 million$45.88 million-2.09
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.5$4.48-4.2%$161.85 million$104.39 million-2.73Earnings Announcement
Analyst Report
Analyst Revision
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.49-4.5%$161.22 millionN/A-7.91Earnings Announcement
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.85-4.7%$156.90 million$2.45 million-1.81Upcoming Earnings
News Coverage
Gap Up
Gamida Cell logo
GMDA
Gamida Cell
1.4$6.60-4.5%$152.59 millionN/A-4.62Earnings Announcement
Analyst Revision
News Coverage
PolarityTE logo
PTE
PolarityTE
1.5$0.98-26.2%$150.00 million$5.65 million-0.59Earnings Announcement
Unusual Options Activity
News Coverage
Gap Down
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.80-7.7%$142.47 millionN/A-3.00Earnings Announcement
Analyst Revision
News Coverage
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.51-7.5%$140.75 millionN/A-1.66
INmune Bio logo
INMB
INmune Bio
1.5$10.25-9.4%$138.73 millionN/A-10.57Analyst Downgrade
Gap Up
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.37-3.1%$133.43 millionN/A0.00Earnings Announcement
Gap Up
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.3$10.02-2.2%$129.76 million$2.33 million0.00News Coverage
Gap Up
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$7.67-2.9%$129.51 millionN/A-2.40Gap Down
Axcella Health logo
AXLA
Axcella Health
1.6$3.41-2.3%$125.61 millionN/A-1.59Analyst Revision
News Coverage
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.31-2.6%$121.45 million$32.12 million-71.62
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.41-5.6%$116.95 millionN/A-3.25
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.78-6.3%$112.36 million$20,000.000.00Upcoming Earnings
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.20-6.4%$112.14 millionN/A-1.52Analyst Revision
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.7$11.15-2.3%$111.36 millionN/A0.00Insider Buying
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.02-0.0%$97.55 million$20.92 million-1.16Earnings Announcement
News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$9.10-4.6%$97.47 millionN/A0.00Analyst Upgrade
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.70-5.4%$96.07 million$23.05 million-1.64Analyst Downgrade
Analyst Revision
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.01-4.0%$92.30 million$140,000.000.00
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$6.04-3.8%$90.07 million$3 million-1.94
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$4.60-14.1%$79.56 million$10,000.000.00Upcoming Earnings
Gap Up
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.11-2.7%$65.68 millionN/A-0.88Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.68-1.6%$57.96 million$420,000.00-1.38Earnings Announcement
News Coverage
Brickell Biotech logo
BBI
Brickell Biotech
1.6$0.82-3.9%$56.89 million$7.92 million-0.34Earnings Announcement
News Coverage
BioCardia logo
BCDA
BioCardia
1.2$3.50-5.1%$55.75 million$710,000.00-1.80Earnings Announcement
News Coverage
Gap Up
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.68-2.2%$54.10 million$10,000.000.00
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.01-0.0%$50.53 million$1.45 million-0.35
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.